On June 10, Tempus AI fell 5.47% in regular trading, trading at $45.965/share, with trading volume of $147 million. The decline comes amid persistent selling by major shareholder LEFKOFSKY ERIC P, whose concentrated share disposals have weighed heavily on market sentiment.

Notably, the Life Sciences Tools & Services sector posted broad gains on the day, with Thermo Fisher Scientific up 2.71%, Waters up 2.38%, and Agilent up 2.09%, highlighting that Tempus AI's weakness is stock-specific rather than sector-driven. The divergence underscores the outsized selling pressure at the individual stock level.

The stock had previously rallied significantly following FDA approval of its xT CDx next-generation sequencing platform, which made the company the first laboratory to hold FDA companion diagnostic approvals for both tumor-only and tumor-normal genomic profiling. The current decline is viewed as an extension of profit-taking combined with sustained institutional selling pressure following that run-up.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)